RxDoctor Payments Data

Marvin Tark

Interventional Pain Medicine · Marietta, GANPI 1548373210

Payments from drug & device makers

What this record shows

Modernatx, Inc. accounts for 82.6% of it on its own, with 12 other manufacturers making up the rest. 2023 is the largest year on record at $1,406, 5.7 times the $245 reported in 2019. That places this record below the midpoint for interventional pain medicine clinicians in GA, where the typical reported total is $4,377.

$1,703in general payments, 2019–2025

Across 27 payments — averaging $63.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$1K
  • Pfizer$55
  • Pacira Therapeutics, Inc.$36
  • Novartis$34
  • Nevro Corp.$31
  • Daiichi Sankyo Inc.$28
  • plus $112 from 7 others
$3,636,502in research payments, 2019–2025

Across 147 payments — averaging $24,738 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$3M
  • Regeneron$339K
  • Acadia Pharmaceuticals Inc$83K
  • GRT US Holding, Inc.$46K
  • Lexicon Pharmaceuticals, Inc.$42K
  • Pfizer$39K
  • plus $46K from 4 others

What the payments were for

  • Travel & lodging$89953%
  • Food & beverage$80447%

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,703 in reported general payments places this provider in the 30th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia →

Other interventional pain medicine in Marietta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →